Tech Company Financing Transactions

Avenzo Therapeutics Funding Round

On 3/26/2024, Avenzo Therapeutics raised $150 million in Series A financing from Deep Track Capital, New Enterprise Associates and Sands Capital Management.

Transaction Overview

Company Name
Avenzo Therapeutics
Announced On
3/26/2024
Transaction Type
Venture Equity
Amount
$150,000,000
Round
Series A
Investors

Deep Track Capital (Lead Investor)

New Enterprise Associates (Lead Investor)

Sands Capital Management (Lead Investor)

Sofinnova Partners (Lead Investor)

Delos Capital

INCE Capital

Quan Capital

TF Capital

Proceeds Purpose
Proceeds from the financing will be used to advance Avenzo's emerging oncology pipeline which is led by AVZO-021, a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor being studied in an ongoing U.S.-based Phase 1 clinical study for the treatment of HR+/HER2- metastatic breast cancer and other advanced solid tumors.

Company Information

Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
12707 High Bluff Drive 200
San Diego, CA 92130
USA
Phone
(858) 239-2944
Website
www.avenzotx.com
Email Address
Not Recorded
Overview
Avenzo Therapeutics is a clinical-stage biotechnology company co-founded in 2022 by Dr. Athena Countouriotis and Dr. Mohammad Hirmand. The company is building and advancing a pipeline of potential best-in-class oncology therapies that target cell cycle control to prevent the aberrant cell proliferation that drives many cancers.
Profile
Avenzo Therapeutics LinkedIn Company Profile
Social Media
Avenzo Therapeutics Company Twitter Account
Company News
Avenzo Therapeutics News
Facebook
Avenzo Therapeutics on Facebook
YouTube
Avenzo Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Athena Countouriotis
  Athena Countouriotis LinkedIn Profile  Athena Countouriotis Twitter Account  Athena Countouriotis News  Athena Countouriotis on Facebook
Chief Financial Officer
Paolo Tombesi
  Paolo Tombesi LinkedIn Profile  Paolo Tombesi Twitter Account  Paolo Tombesi News  Paolo Tombesi on Facebook
Chief Medical Officer
Mohammad Hirmand
  Mohammad Hirmand LinkedIn Profile  Mohammad Hirmand Twitter Account  Mohammad Hirmand News  Mohammad Hirmand on Facebook
Vice President
Melissa Fitzgerald
  Melissa Fitzgerald LinkedIn Profile  Melissa Fitzgerald Twitter Account  Melissa Fitzgerald News  Melissa Fitzgerald on Facebook
Vice President
Ming Lu
  Ming Lu LinkedIn Profile  Ming Lu Twitter Account  Ming Lu News  Ming Lu on Facebook
Vice President
Minal Mehta
  Minal Mehta LinkedIn Profile  Minal Mehta Twitter Account  Minal Mehta News  Minal Mehta on Facebook
VP - Bus. Development
Scott Lipman
  Scott Lipman LinkedIn Profile  Scott Lipman Twitter Account  Scott Lipman News  Scott Lipman on Facebook
VP - General Counsel
Brian Sun
  Brian Sun LinkedIn Profile  Brian Sun Twitter Account  Brian Sun News  Brian Sun on Facebook
VP - Marketing
Carla Taub
  Carla Taub LinkedIn Profile  Carla Taub Twitter Account  Carla Taub News  Carla Taub on Facebook
VP - Operations
Melissa Holmes
  Melissa Holmes LinkedIn Profile  Melissa Holmes Twitter Account  Melissa Holmes News  Melissa Holmes on Facebook
VP - Regulatory Affairs
Naresh Nayyar
  Naresh Nayyar LinkedIn Profile  Naresh Nayyar Twitter Account  Naresh Nayyar News  Naresh Nayyar on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/26/2024: Arevo venture capital transaction
Next: 3/26/2024: 0G Labs venture capital transaction

 

Share this article

 

Where The Data Comes From

We record every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.